Atika Capital Management’s DexCom DXCM Stock Holding History

Atika Capital Management’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-160,000	Closed	-$3.8M	–	94
2018 Q2	$3.8M	Buy	+160,000	New	+$3.39M	0.73%	52

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Atika Capital Management's DXCM Position: Q4 2024 in Review

Atika Capital Management sold out of DexCom (DXCM) in Q4 2024, closing a stake of 87,000 shares — an estimated $5.83M sold.

Atika Capital Management first reported a position in DXCM in Q1 2018 and held it in 24 quarters. The position peaked at $16.7M in Q3 2018. 950 funds tracked by Wall St. Rank hold DXCM as of Q4 2024.

Atika Capital Management reported no remaining DexCom position as of Q4 2024 after selling out during the quarter.
Atika Capital Management sold 87,000 DexCom shares in Q4 2024, an estimated $5.83M.
Atika Capital Management first reported a position in DexCom in Q1 2018 and held it in 24 quarters.
Atika Capital Management's DexCom position peaked at $16.7M in Q3 2018.
950 funds tracked by Wall St. Rank held DexCom as of Q4 2024.

Based on Atika Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.